| Eli Lilly Bets Big on Dicerna’s Gene-Silencing Technology |
Abstract
pdf
html
|
|
Michelle Liu |
|
| Novartis and Pfizer to Explore NASH Combinations |
Abstract
pdf
html
|
|
Michelle Liu |
|
| Gilead Boosts Oncology Pipeline with Tango Collaboration |
Abstract
pdf
html
|
|
Michelle Liu |
|
| Merck & Co. Continues to Look at NK Cell Engager Therapies with Dragonfly Therapeutics Pact |
Abstract
pdf
html
|
|
Michelle Liu |
|
| Sanofi Collaborates with Denali for its RIPK1 Programme |
Abstract
pdf
html
|
|
Michelle Liu |
|
| Janssen Adds Yuhan’s Lazertinib to its Oncology Pipeline in a US$1.25 B Deal |
Abstract
html
pdf
|
|
Jawala Prasad & Michelle Liu |
|
| AstraZeneca Expands Immuno-Oncology Collaboration with Innate Pharma |
Abstract
pdf
html
|
|
Jasmine Kalsi & Michelle Liu |
|
| LEO Pharma Enters into Rare Skin Diseases with US$760 M Deal with PellePharm |
Abstract
pdf
html
|
|
Sharath Chandra Nakka & Michelle Liu |
|
| United Therapeutics Licenses Arena’s Ralinepag for US$800 M Upfront |
Abstract
pdf
html
|
|
Michelle Liu |
|
| Boston Scientific Continues M&A Spree with US$4.2 B BTG Deal |
Abstract
pdf
html
|
|
Jawala Prasad & Michelle Liu |
|
